However, Fizazi et al. [170] reported an anti-IL-6 monoclonal antibody, siltuximab, inhibited STAT3 expression, but did not find a survival improvement in patients with advanced prostate cancer. This evidence concerns the gene IL6 and prostate carcinoma.